Archive for May, 2011

OPTR Dificid FDA approval. MRNA reverse split vote soon. ALIM mixed shelf

May 27, 2011 No Comments by

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the FDA approved DIFICID (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven […]

Daily News Read more

MAPP files Levadex NDA for migraine. CLSN raises cash

May 27, 2011 No Comments by

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that it has submitted its NDA to the FDA for LEVADEX orally inhaled migraine drug for the potential acute treatment of migraine in adults. Celsion Corporation (NASDAQ: CLSN) announced it will issue 3,218,612 shares of common stock and warrants, The Common Stock and Warrants will be sold in units […]

Daily News Read more

OXGN short of cash. RIGL raising cash + ABIO BCRX DVAX :

May 26, 2011 No Comments by

OXiGENE, INC (Nasdaq: OXGN) in an SEC filing yesterday noted that it has cash through to only August this year. It must also compliance with the the $35 million minimum market value of listed securities requirement OR the minimum $2.5 million stockholders equity requirement prior to June 13, 2011, or will be delisted from The […]

Daily News Read more

TSRX raises cash, VVUS reiterates Avanafil NDA filing due 2Q, PPHM

May 25, 2011 No Comments

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced the initiation of an investigator-sponsored trial (IST) for patients with castration-resistant prostate cancer (CRPC). 31 second-line CRPC patients will be treated with bavituximab in combination with the chemotherapeutic agent cabazitaxel. VIVUS, Inc. (NASDAQ: VVUS) today reiterated that they plan to file their NDA for avanafil for the treatment […]

Read more

Upcoming votes for Reverse Splits and to increase Authorised Shares

May 24, 2011 No Comments

Over the next month or so, many companies will be holding shareholder meetings to vote on various issues such as electing directors or making adjustments to Equity Incentive plans. However, some companies also use the meetings to request permission to increase the number of Authorised Shares and to enforce Reverse Splits. It should be noted […]

Read more

ONTY initiates Phase 2 PX-866. TSPT TO-2061 data due mid-2012

May 24, 2011 No Comments

Oncothyreon Inc. (Nasdaq: ONTY) today announced it has initiated the Phase 2 portion of its ongoing Phase 1-2 trial of PX-866 in combination with the chimeric monoclonal antibody cetuximab (Erbitux) in patients with metastatic colorectal carcinoma (CRC) or progressive, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). TRANSCEPT PHARMACEUTICALS, INC (Nasdaq: […]

Read more

May 22, 2011

May 22, 2011 No Comments

Some short and long term potential catalysts as of May 22 2011 (share prices as at the close of trading Friday, May 20, 2011). See the links in the FDA Calendar for more details about each catalyst. The possible catalysts listed below represent both short and long opportunities. It is NOT a recommendation to take […]

Read more

HGSI ACOR receive CHMP approval. IMGN raisng cash + CTIC SCLN

May 20, 2011 No Comments

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) filed a SEC Filing today seeking shareholder approval on June 30 to increase Authorised Shares from 75m to 100m. GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending marketing authorisation […]

Read more

CORT additional Phase 3 CORLUX data to be presented June 4 + OMER INFI

May 19, 2011 No Comments

Corcept Therapeutics Incorporated (NASDAQ: CORT), today announced that detailed data from the Phase 3 study of CORLUX in Cushings Syndrome will be presented at the Endocrine Society 93rd Annual Meeting (ENDO) held June 4 – 7, 2011 in Boston. On April 15, 2011, they submitted their NDA. The abstract (No. OR09-5) will be presented on […]

Read more

ASCO 2011 Abstracts have been added to the ASCO Calendar

May 19, 2011 No Comments

The BioPharmCatalyst ASCO 2011 Calendar has been completed with the addition of ALL abstracts of companies that were originally listed on the calendar. Just click on the ASCO tab above and you will find that abstracts have been added by clicking on the Abstract Link number. There are many companies that are just presenting previously […]

Read more

APPA hope to increase Authorised Shares to 1.5b. CLDX AEZS rasing cash. NBY fail

May 18, 2011 No Comments

A.P. Pharma, Inc. (OTCQB: APPA) filed a Pre14a saying they intend to ask shareholders on June 29 to increase the number of Authorised Shares from 100m to a whopping 1.5b! Aeterna Zentaris Inc. (NASDAQ: AEZS) released their quarterly results today noting that in April alone they had issued a total of approximately 7.3 million common […]

Read more